8-K
Processa Pharmaceuticals, Inc. (PCSA)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM8-K
CURRENTREPORT
PURSUANTTO SECTION 13 OR 15(d) OF THE
SECURITIESEXCHANGE ACT OF 1934
Dateof Report (Date of earliest event reported): February 13, 2020
Commission file number 333-184948
PROCESSAPHARMACEUTICALS, INC.
(Exactname of Registrant as Specified in its Charter)
| Delaware | 45-1539785 |
|---|---|
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification Number) |
| 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076 | |
| --- | |
| (Address of Principal Executive Offices, Including Zip Code) | |
| (443) 776-3133 | |
| --- | |
| (Registrant’s Telephone Number, Including Area Code) | |
| (Former Name or Former Address, if Changed Since Last Report) | |
| --- |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| [ ] | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title<br> of each class | Trading<br> symbol(s) | Name<br> of each exchange on which registered |
|---|---|---|
| OTC | PCSA | Processa<br> Pharmaceuticals |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging<br> growth company [X] |
|---|
| If<br> an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period<br> for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<br> [ ] |
| --- |
Item7.01. Regulation Disclosure.
Incorporated by reference is a press release issued by the Registrant on February 13, 2020 attached as Exhibit 99.1, announcing the appointment of Geraldine Pannu to the Company’s Board of Directors.
Item 9.01. FinancialStatements and Exhibits
| Exhibit No. | Exhibit Description |
|---|---|
| 99.1 | Press release announcing appointment of a new Director. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on February 13, 2020.
| PROCESSA PHARMACEUTICALS, INC. | |
|---|---|
| Registrant | |
| By: | /s/ David Young |
| David<br> Young | |
| Chief<br> Executive Officer |
Exhibit 99.1
| FOR<br> IMMEDIATE RELEASE | For<br> More Information: |
|---|---|
| Patrick<br> Lin | |
| plin@processapharma.com | |
| 925-683-3218 |
PROCESSA PHARMACEUTICALS APPOINTS
GERALDINE PANNU AS AN INDEPENDENT DIRECTOR TO THE BOARD OF DIRECTORS
HANOVER, MD – February 13, 2020 – Processa Pharmaceuticals, Inc. (OTC: PCSA) a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, announced today that Geraldine Pannu was appointed to the Board of Directors.
Ms. Pannu has over 25 years’ experience in investment and financial management, fund operations, consulting and marketing. She is currently the Founding and Managing Partner of GLTJ Pioneer Capital that specializes in land acquisition, entitlement and vertical development of multifamily, student and senior housing in the San Francisco Bay Area. Previously, Ms. Pannu was the COO and Managing Partner for ChinaRock Capital Management, a leading hedge and venture capital fund company. She previously worked in McKinsey & Co, Monitor Company as management consultant. She had successfully raised capital for several hedge, venture capital and real estate funds. She also helped start-up companies to expand and diversify business categories, client verticals and grow revenue. Ms. Pannu was born in Shanghai and grew up in Hong Kong. She received her Bachelor of Business Administration degree from the Chinese University of Hong Kong and an MBA from Harvard Business School. She is fluent in English, Mandarin, Cantonese and Shanghainese.
“We are pleased to welcome Geraldine to our Board of Directors at this important stage of Processa’s evolution. Her strong investment and finance skills as well as leadership experience will complement our existing board,” said Dr. David Young, CEO of Processa Pharmaceuticals.
“I am excited about joining Processa’s Board,” stated Ms. Pannu. “The Processa team has accomplished so much in a short amount of time and I look forward to working alongside my fellow Board members and company management as we continue to build long term shareholder value.”
AboutProcessa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The company acquired the assets of Promet Therapeutics, LLC in October of 2017 and has assembled a proven regulatory science product development team, management team, and Board of Directors. The Processa Team’s expertise is in developing drug products from IND enabling studies to NDA submission. The Company’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. For more information, please visit http://www.processapharma.com
Forward-LookingStatements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.